4.7 Article

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Journal

Publisher

SPRINGER
DOI: 10.1007/s00259-021-05307-1

Keywords

FAPI PET; CT; FDG PET; CT; Cancer-associated fibroblast; Various cancer diseases

Funding

  1. Projekt DEAL

Ask authors/readers for more resources

The study aimed to compare Ga-68-FAPI and F-18-FDG in organ biodistribution and tumor uptake in PET/CT, showing that Ga-68-FAPI has lower uptake in most normal tissues compared to F-18-FDG, resulting in significantly higher TBRs at some sites for Ga-68-FAPI.
Purpose FAPI ligands (fibroblast activation protein inhibitor), a novel class of radiotracers for PET/CT imaging, demonstrated in previous studies rapid and high tumor uptake. The purpose of this study is the head-to-head intra-individual comparison of Ga-68-FAPI versus standard-of-care F-18-FDG in PET/CT in organ biodistribution and tumor uptake in patients with various cancers. Material and Methods This international retrospective multicenter analysis included PET/CT data from 71 patients from 6 centers who underwent both Ga-68-FAPI and F-18-FDG PET/CT within a median time interval of 10 days (range 1-89 days). Volumes of interest (VOIs) were manually drawn in normal organs and tumor lesions to quantify tracer uptake by SUVmax and SUVmean. Furthermore, tumor-to-background ratios (TBR) were generated (SUVmax tumor/ SUVmax organ). Results A total of 71 patients were studied of, which 28 were female and 43 male (median age 60). In 41 of 71 patients, the primary tumor was present. Forty-three of 71 patients exhibited 162 metastatic lesions. Ga-68-FAPI uptake in primary tumors and metastases was comparable to F-18-FDG in most cases. The SUVmax was significantly lower for Ga-68-FAPI than F-18-FDG in background tissues such as the brain, oral mucosa, myocardium, blood pool, liver, pancreas, and colon. Thus, Ga-68-FAPI TBRs were significantly higher than F-18-FDG TBRs in some sites, including liver and bone metastases. Conclusion Quantitative tumor uptake is comparable between Ga-68-FAPI and F-18-FDG, but lower background uptake in most normal organs results in equal or higher TBRs for Ga-68-FAPI. Thus, Ga-68-FAPI PET/CT may yield improved diagnostic information in various cancers and especially in tumor locations with high physiological F-18-FDG uptake.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer

Kim Magaly Pabst, Robert Seifert, Nader Hirmas, Martina Broecker-Preuss, Manuel Weber, Wolfgang Peter Fendler, Timo Bartel, Sarah Theurer, Ken Herrmann, Rainer Goerges

Summary: The aim of this study was to investigate the predictive power of single stimulated thyroglobulin (s-Tg) and single highly sensitive measured, unstimulated thyroglobulin (u-hsTg) measurements for recurrence-free survival (RFS) in long-term follow-up of patients with differentiated thyroid cancer (DTC). Results showed that both s-Tg and u-hsTg had a significant predictive power for RFS, with u-hsTg and patient age being significantly associated with tumor recurrence.

ENDOCRINE CONNECTIONS (2023)

Article Medicine, General & Internal

The SARS-COV-2 Seroprevalence among Oncology Patients

Mankgopo Kgatle, Rajesh Das, Ismaheel Lawal, Tebatso Boshomane, Kgomotso Mokoala, Cattleya Gaspar, Lydia Mbokazi, Nonhlanhla Nkambule, Veronique Gow, Honest Ndlovu, Yonwaba Mzizi, Joseph Chalwe, Jeaneth Diphofa, Dinah Mokobodi, Nobuhle Gxekwa, Lusanda Zongo, Tinashe Maphosa, Mariza Vorster, Sheynaz Bassa, Amouda Venkatesan, Richard Khanyile, Yunus Munga, Thomas Ebenhan, Jan Rijn Zeevaart, Mike Sathekge

Summary: The study aimed to estimate the SARS-CoV-2 seroprevalence among solid tumour patients attending a hospital for cancer diagnosis and treatment. Using COVID-19 IgG/IgM rapid tests, the researchers found a seroprevalence of 33.2% among asymptomatic patients with solid tumours. The seroprevalence increased significantly from the second to the fourth waves, with a high percentage of asymptomatic cases. Patients with breast, gynaecologic, and prostate cancers showed higher SARS-CoV-2 seropositivity.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines

Ida Sonni, Alan Dal Pra, Dylan P. O'Connell, Zachary Ells, Matthias Benz, Kathleen Nguyen, Stephanie M. Yoon, Jie Deng, Clayton Smith, Tristan Grogan, Nickolas G. Nickols, Minsong Cao, Amar U. Kishan, Jeremie Calais

Summary: The aim of this study was to analyze the patterns of prostate bed recurrence in prostate cancer patients experiencing PSA persistence or biochemical recurrence after radical prostatectomy using 68Ga-PSMA-11 PET/CT in relation to the RTOG CTVs. The results suggest that 68Ga-PSMA PET can be a valuable tool for guiding SRT planning to improve treatment outcomes.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [Lu-177]PSMA Radioligand Therapy: An International Multicenter Retrospective Study

Masatoshi Hotta, Andrei Gafita, Vishnu Murthy, Matthias R. Benz, Ida Sonni, Irene A. Burger, Matthias Eiber, Louise Emmett, Andrea Farolfi, Wolfgang P. Fendler, Manuel M. Weber, Michael S. Hofman, Thomas A. Hope, Clemens Kratochwil, Johannes Czernin, Jeremie Calais

JOURNAL OF NUCLEAR MEDICINE (2023)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy

Vishnu Murthy, Martin Allen-Auerbach, Richard Lam, Dawn Owen, Johannes Czernin, Jeremie Calais

JOURNAL OF NUCLEAR MEDICINE (2023)

Review Pharmacology & Pharmacy

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review

Sipho Mdanda, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, Jan Rijn Zeevaart

Summary: The radioisotope Ac-225 has great potential for use in radionuclide therapy, but its multiple daughter nuclides can cause toxicity in unintended organs. Nanotechnology offers strategies to keep the Ac-225 daughters from escaping the targeted site. This review explores the advancements and potential applications of targeted radionuclide therapy, specifically with Ac-225, and highlights the importance of using nanomaterials to improve therapeutic efficacy.

PHARMACEUTICS (2023)

Article Oncology

Correlation between [Ga-68]Ga-FAPI-46 PET Imaging and HIF-1 & alpha; Immunohistochemical Analysis in Cervical Cancer: Proof-of-Concept

Kgomotso M. G. Mokoala, Ismaheel O. Lawal, Letjie C. Maserumule, Meshack Bida, Alex Maes, Honest Ndlovu, Janet Reed, Johncy Mahapane, Cindy Davis, Christophe van de Wiele, Gbenga Popoola, Frederik L. Giesel, Mariza Vorster, Mike M. Sathekge

Summary: Hypoxia is common in cervical cancer and upregulates the presence and function of CAFs. HIF-1a plays a key role in the physiological response to hypoxia. [Ga-68]Ga-FAPI PET can be used as an indirect tracer for mapping hypoxia by correlating image findings to HIF-1a expression. FAPI-TV is a better predictor of metastatic disease than SUVmax.

CANCERS (2023)

Article Oncology

Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Karim Fizazi, Ken Herrmann, Bernd J. Krause, Kambiz Rahbar, Kim N. Chi, Michael J. Morris, Oliver Sartor, Scott T. Tagawa, Ayse T. Kendi, Nicholas Vogelzang, Jeremie Calais, James Nagarajah, Xiao X. Wei, Vadim S. Koshkin, Jean-Mathieu Beauregard, Brian Chang, Ray Ghouse, Michelle DeSilvio, Richard A. Messmann, Johann de Bono

Summary: In the VISION study, lutetium-177 (177Lu) Lu-PSMA-617 improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Additional results showed improvements in health-related quality of life, pain, and symptomatic skeletal events.

LANCET ONCOLOGY (2023)

Meeting Abstract Urology & Nephrology

MOLECULAR CORRELATES WITH PSMA EXPRESSION IN PROSTATE CANCER

Adam Weiner, Eric Li, J. J. Zhang, Elai Davicioni, Edward Schaeffer, Ashley Ross, Luca Valle, Paul Boutros, Jeremie Calais, Amar Kishan, Robert Reiter

JOURNAL OF UROLOGY (2023)

Meeting Abstract Urology & Nephrology

PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PROSTATE BIOPSY

David Kuppermann, Jeremie Calais, Leonard Marks

JOURNAL OF UROLOGY (2023)

Meeting Abstract Urology & Nephrology

PSMA-GUIDED PROSTATE BIOPSY

David Kuppermann, Jeremie Calais, Elizabeth Tran, Samantha Gonzalez, Merdie Delfin, Leonard Marks

JOURNAL OF UROLOGY (2023)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Head-to-head comparison of 68Ga-PSMA-11 PET with 99mTc-MDP bone scan for detection of bone disease in prostate cancer patients with biochemical progression during ADT: a single center prospective study

A. Gafita, R. Alano, M. Rettig, J. Shen, W. Armstrong, T. R. Grogan, S. Liu, M. R. Benz, J. Czernin, J. Calais

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Radioligand Therapy in GBM: Fibroblast Activation Protein (FAP) Promises

P. Jeanjean, S. Kwock, T. Cloughesy, J. Calais, J. Czernin, G. Carlucci, D. Nathanson, C. Mona, E. Besserer-Offroy

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Meeting Abstract Oncology

Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

Lisa M. Gudenkauf, Melody Chavez, Melinda Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha Hoogland, Kathleen Nguyen, Laura B. Oswald, Heather S. L. Jim, Ghassan El-Haddad, Wolfgang Peter Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez

JOURNAL OF CLINICAL ONCOLOGY (2023)

Meeting Abstract Oncology

Radiographic-pathologic concordance in the workup of locally radiorecurrent prostate cancer.

Luca Faustino Valle, Jeremie Calais, Leonard S. Marks, Steven Raman, Robert Evan Reiter, Matthew Rettig, John Shen, Johannes Czernin, Adam B. Weiner, Michael L. Steinberg, Nicholas George Nickols, Albert J. Chang, Paul Christopher Boutros, Huihui Ye, Masatoshi Hotta, Rong Rong Huang, Amar Upadhyaya Kishan

JOURNAL OF CLINICAL ONCOLOGY (2023)

No Data Available